Takeaways are back for Bills' defense in stuffing Washington

The Buffalo Bills forced three turnovers Sunday, and the Washington Football Team finished with 290 yards of offense, unable ...
The Regulatory Review

AI as “Arbitrary” Intelligence

Federal Agencies’ growing use of AI raises questions about how judges can adequately review those agencies’ decisions.
Pharmabiz

Pfizer’s Hympavzi receives European approval to treat adults and adolescents with haemophilia A or B with inhibitors

Pfizer Inc. announced that the European Commission (EC) has granted marketing authorization to expand the approved indication for Hympavzi (marstacimab) to include patients 12 years of age and older ...
Armed robbery in Revesby

EU OKs Pfizer's HYMPAVZI for Hemophilia A/B Treatment

Pfizer Inc. (NYSE: PFE)today announced that the European Commission (EC) has granted marketing authorization to expand the approved indication for HYMPAVZI ® (marstacimab) to include patients 12 years ...
Nasdaq

European Commission Approves Pfizer’s HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitors

Approval in patients ages 12 and older based on Phase 3 data demonstrating superior bleed reduction to on-demand therapy, with continued benefit observed in open-label extension study HYMPAVZI is the ...
Rutland Herald

European Commission Approves Pfizer’s HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitors

Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization to expand the approved indication for HYMPAVZI ® (marstacimab) to include patients 12 ...
The Financial

Game-Changer for Hemophilia: EU Approves Weekly Hympavzi

Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization to expand the approved indication for HYMPAVZI® (marstacimab) to include patients 12 years ...